Opioid Receptor Agonists - Pipeline Insight, 2024

Opioid Receptor Agonists - Pipeline Insight, 2024

DelveInsight’s, “Opioid Receptor Agonists - Pipeline Insight, 2024” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Opioid Receptor Agonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Opioid Receptor Agonists Understanding

Opioid Receptor Agonists: Overview

Opioids are a group of analgesic agents commonly used in clinical practice. Opioids produce their pharmacological effects through the activation of opioid receptors, which include three main types, mu (MOR), delta (DOR) and kappa (KOR) of which the MOR type is the primary target of most clinically used opioid analgesics. Opioid agonists bind to G-protein coupled receptors to cause cellular hyperpolarisation. Most clinically relevant opioid analgesics bind to MOP receptors in the central and peripheral nervous system in an agonist manner to elicit analgesia. Opioids may also be classified according to their mode of synthesis into alkaloids, semi-synthetic and synthetic compounds.

""Opioid Receptor Agonists - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Opioid Receptor Agonists pipeline landscape is provided which includes the disease overview and Opioid Receptor Agonists treatment guidelines. The assessment part of the report embraces, in depth Opioid Receptor Agonists commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Opioid Receptor Agonists collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Opioid Receptor Agonists R&D. The therapies under development are focused on novel approaches to treat/improve Opioid Receptor Agonists.

Opioid Receptor Agonists Emerging Drugs Chapters

This segment of the Opioid Receptor Agonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Opioid Receptor Agonists Emerging Drugs

• LTX-03: Acura Pharmaceuticals

LTX-03 is being developed by Acura Pharmaceuticals. In June 2020, Acura Pharmaceuticals entered into License, Development and Commercialization Agreement, which was amended in October 2021, with Abuse Deterrent Pharmaceuticals, LLC, (“AD Pharma”) and a special purpose company representing a consortium of investors that will finance Acura’s operations through July 2021 and reimburse for development of LTX-03. AD Pharma has exclusive commercialization rights in the United States to LTX-03.

• TRV-734: Trevena

Trevena is developing TRV734 for use in medication-assisted therapy for the treatment of opioid use disorder. It targets the mu receptor, but with an optimized mechanism of action that preferentially engages the signaling pathway responsible for therapeutic effect, with reduced activation of the signaling pathway responsible for mu receptor-mediated adverse effects.

Further product details are provided in the report……..

Opioid Receptor Agonists: Therapeutic Assessment

This segment of the report provides insights about the different Opioid Receptor Agonists drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Opioid Receptor Agonists

There are approx. 40+ key companies which are developing the therapies for Opioid Receptor Agonists. The companies which have their Opioid Receptor Agonists drug candidates in the most advanced stage, i.e. Phase II include, Acura Pharmaceuticals.

• Phases

DelveInsight’s report covers around 40+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Opioid Receptor Agonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Opioid Receptor Agonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Opioid Receptor Agonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Opioid Receptor Agonists drugs.

Opioid Receptor Agonists Report Insights

• Opioid Receptor Agonists Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Opioid Receptor Agonists Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Opioid Receptor Agonists drugs?
• How many Opioid Receptor Agonists drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Opioid Receptor Agonists?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Opioid Receptor Agonists therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Opioid Receptor Agonists and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Trevena
• Titan Pharmaceuticals
• Lumosa Therapeutics
• Astraea Therapeutics
• Alar Pharmaceuticals
• Ensysce Biosciences

Key Products

• TRV-734
• TP-2021
• TRV-250
• LT5001
• ALA-1000
• PF 614